Drawing for FURIN

USPTO serial 78059170

FURIN

Reviewed by CopyMark Law Group

Status 601
Filing date
Status date
Registration date
—
Examiner
GOLDEN, JAMES B
Law office
FILE REPOSITORY (FRANCONIA)

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with FURIN?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
001Genetically engineered animal cells for in vitro production for medical or veterinary use of biological active recombinant proteins or genetically engineered derivatives thereof using co-expression of a gene encoding a proprotein or precursor protein and a gene encoding a proprotein convertase, including genetically engineered animals for in vivo production for medical or veterinary use of biologically active recombinant proteins or genetically engineered derivatives thereof using co-expression of a gene encoding a proprotein or precursor protein and a gene encoding a proprotein convertase, test-tube manufacture for medical or veterinary use of biologically active recombinant proteins genetically engineered derivatives thereof from a proprotein or precursor protein using a proprotein convertase, biologically active recombinant proteins or genetically engineered derivatives of plasma proteins such as blood clotting factors and albumin, biological active recombinant proteins or genetically engineered derivatives of brain proteins such as neuropeptides, polypeptide hormones and receptors, biologically active recombinant proteins or genetically engineered derivatives of growth and differentiation factors such as for instance members of the TGF- BETA/BMP superfamily, biologically active recombinant proteins or genetically engineered derivatives of growth factor receptors such as the type I insulin-like growth factor receptor, biologically active recombinant proteins or genetically engineered derivatives of viral proteins from viruses, such as for example HIV, Ebola virus, Marburg virus, influenza virus, biologically active recombinant protein or genetically engineered derivatives of toxins e.g. anthrax toxin, biologically active recombinant proteins or genetically engineered derivatives of a variety of enzymes such as metalloproteinases and proprotein convertases, biologically active recombinant proteins or genetically engineered derivatives of several cell-surface receptors, adhesion molecules, signaling proteins and extracelluar-martix proteins, biologically active recombinant proteins or genetically engineered derivatives of proteins or fragments thereof for production of vaccines, biological active recombinant proteins or genetically engineered derivatives of any natural occurring of artificially designed proprotein or precursor protein which requires the action of a proprotein convertase for cleavage into biologically active componentsACTIVE—
005biological , chemical, and enzyme preparations for medical and veterinary purposes, namely pharmaceutical preparations used in the treatment of mammals with enzyme insufficiency or deficiency; chemical reagents for medical and veterinary use, namely, clinical medical reagents; medical diagnostic reagents; medicines for human and veterinary purposes, namely, pharmaceutical preparations used in the treatment of mammals with enzyme insufficiency or deficiencyACTIVE—
042Biological research, namely biomedical research, biochemical research, genetic research, animal cell biotechnology research, agricultural research, and viral research; blood bank services; research and development of new pharmaceutical and research products for others; Professional consultancy, namely, technical consultation in the field of biomedical research, biochemical research, genetic research, animal cell biotechnology research, agricultural research and viral researchACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 30, 2003ABN1ABANDONMENT - EXPRESS MAILED—
Mar 19, 2003CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 1, 2002CNFRFINAL REFUSAL MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Aug 21, 2002ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Jun 26, 2002NPUBNOTICE OF PUBLICATION—
Apr 18, 2002TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Feb 5, 2002CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 6, 2001CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 20, 2001CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 17, 2001DOCKASSIGNED TO EXAMINER—

Frequently asked questions

Related guidance